Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Moderate-to-severe Hidradenitis Suppurativa
NCT05997277Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: Median Change From Baseline in Number of Inflammatory Lesion Counts (AN Count) at 16 weeks. Started Nov 2023; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05997277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997277.